Please login to the form below

Not currently logged in
Email:
Password:

nintedanib

This page shows the latest nintedanib news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

years. Two drugs have been approved for IPF - Roche's Esbriet (pirfenidone) and Boehringer Ingelheim's Ofev (nintedanib) - but while they can delay disease progression neither has a significant impact on

Latest news

More from news
Approximately 9 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    The drug is predicted to take a 50% share of the estimated $2bn IPF market, the main competitor being Boehringer Ingelheim's nintedanib currently in late stage development.  .

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    It's a method that is also seeing Boehringer enter the increasingly attractive rare diseases market through its investigational drug nintedanib, which is in studies assessing its effectiveness as a treatment ... This is in addition to nintedanib's

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics